CTOs on the Move

Sanofi Genzyme

www.sanofigenzyme.com

 
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Lupin

Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Evotec

Evotec is a Winchester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

REGENCare

💉THE Leader in Regenerative Medicine 👉🏼Head of SSCI & @svlcatl 📞678-568-2309 ♻️We are a green company with one motto: save yourself, save the planet 🌍

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

Lenoss Medical